It has been reported that a “loss of imprinting” of insulin-like growth factor II (IGF2) and the H19 large intergenic non-coding RNA coding regions is found in 100% of chronic myeloid leukemia (CML), 80% of ovarian tumors, 70% of Wilms’ tumors, 66% of colorectal cancer, 56% of Barrett’s esophagus, 50% of renal-cell carcinomas, 50% of esophageal cancer, 47%–85% of lung adenocarcinoma and 30% of meningioma [110]. This evidence concerns the gene IGF2 and esophageal cancer.